| Table Header | Table Header |
|---|---|
|
Catalog Number |
ASHU-00102 |
|
Model Name |
PD-L1 & CTLA4 |
|
Strain Name |
C57BL/6-Ctla4em1(hCTLA4)Cd274em1(hPD – L1)/Asc |
|
GENE Synonyms |
Cd152, Ly-56, Ctla-4, B7h1, Pdl1, Pdcd1l1, Pdcd1lg1, A530045L16Rik |
|
Human Orthologs |
CTLA4, CD274 |
|
Ensembl ID |
ENSMUSG00000026011, ENSMUSG00000016496 |
|
MGI ID |
88556, 1926446 |
|
NCBI ID |
12477, 60533 |
|
Background |
C57BL/6 |
|
Coat Color |
Black |
|
Mutation Type |
Humanized |
|
Model Type |
Humanized |
|
Research Application |
Immunotherapy, cancer research, drug screening |
|
Model Color |
Black |
Strategy for Generating Humanized PD-L1 (ASHU-00062) Mouse Model
Strategy for Generating Humanized CTLA4 (ASHU-00014) Mouse Model
Figure 1. Splenocytes from homozygous hPD-L1/hCTLA4 mice were analyzed by flow cytometry after activation. The murine Pd-l1 (mPD-L1) and Ctla4 (mCTLA4) positive cells were detectable in wild type (WT) C57BL/6 mice, while the human (hPD-L1) and human (hCTLA4) positive cells were detectable in the homozygous hCTLA4/hPD-L1 mice.
Figure 2. hCTLA-4/PD-L1 mice+ MC38 cells efficacy studies. We have developed a CTLA-4/PD-L1 dKI humanized model and tested the combined treatment of Yervoy and Tecentriq, and then observed improved efficacy in the combination treatment.
Fill out the contact form below and a team member will be in touch within one business day.
